A Business split in two directions

NIOX Group (LSE:NIOX), which makes point-of-care devices that measure fractional exhaled nitric oxide (FeNO) to help diagnose and manage asthma, has published no substantive regulatory announcement in the 24 hours to the early morning of 3 November 2026. Its most recent results, the interim figures published on 29 September 2026, showed its two Revenue streams moving in opposite directions and placed weight on the second half of the year.

For the six months to 30 June 2026, revenue fell 5% to £24.0m from £25.2m, according to the results. Clinical revenue, from sales of devices and tests to healthcare providers, rose 3% to £20.6m. Clinical Trials revenue, generated mainly from pharmaceutical companies using the devices in clinical trials, fell by roughly a third to £3.4m. Gross Margin improved to about 71% from 70%, adjusted EBITDA was £8.3m, and profit for the period was reported at £5.9m.

What management expects from the second half

The company said it expected the second half to be better than the first, citing three drivers: the rollout of its new NIOX PRO device, higher reimbursement in Japan, and increased clinical trial activity. It said it expected full-year revenue and adjusted EBITDA to be in line with current market consensus.

In a trading update on 28 July 2026, NIOX said NIOX PRO had received a CE mark and UK MHRA approval in the first half, with submissions in the US and Japan in progress and approvals expected in the second half. That update cited consensus at the time of about £50.5m of revenue and £17.5m of adjusted EBITDA for 2026, which would imply a second-half revenue figure of about £26.5m. Those consensus numbers are analyst forecasts, not company guidance, and may have changed since.

Why the device matters

NIOX PRO is the next generation of the company's core FeNO device. In our interpretation, its importance lies less in a one-off device sale than in the recurring test consumables that follow each installation, which make up much of clinical revenue. A smooth launch in Europe and the UK, followed by approvals in the US and Japan, would broaden the installed base on which those recurring sales depend. Japanese reimbursement changes could similarly raise the revenue generated from each test.

Clinical trials revenue is harder to predict, because it depends on the timing of pharmaceutical trials outside NIOX's control. The first-half decline shows how quickly that line can swing. The company did not quantify how much of the expected second-half improvement each driver should contribute.

Capital return and balance sheet

Alongside the interims, NIOX proposed a tender offer, which shareholders approved on 21 October. On 22 October it said it had bought 15,625,000 shares at 80p each, returning about £12.5m in total, leaving 405,241,313 shares in issue. Substantial Shareholder Harwood Capital participated, a related party transaction. Payment to certificated holders was due by 3 November. The company had reported cash of £16.8m and no Debt at 30 June, and the results indicated pro forma cash of about £5m after the tender. The shares were about 66.6p at the close of the 2 November session.

Risks and what to watch

The main risks are regulatory timing in the US and Japan, the pace at which customers switch to the new device, and further Volatility in clinical trials revenue. A lower cash balance after the tender also leaves less buffer if trading disappoints. Healthcare budgets and how widely clinical guidelines support routine FeNO testing are further dependencies outside the company's control. The next markers are any NIOX PRO approval announcements and a full-year trading update, for which no date has been given.